{"id":"W2474699717","doi":"10.1634/theoncologist.2016-0097","title":"Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; AstraZeneca; Pfizer","keywords":"Medicine; Palbociclib; Fulvestrant; Neutropenia; Placebo; Metastatic breast cancer; Internal medicine; Adverse effect; Febrile neutropenia; Oncology; Common Terminology Criteria for Adverse Events; Breast cancer; Cancer; Chemotherapy; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002269588,0.0007260456,0.001212541,0.0005020935,0.0002437266,0.0005817977,0.0005429382,0.0006464577,0.00328954],"category_scores_gemma":[0.001360831,0.0003102725,0.001353721,0.0006274762,0.0005220337,0.0004232198,0.0002213792,0.001114115,0.0003854533],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006468981,"about_ca_system_score_gemma":0.0009759552,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005549605,"about_ca_topic_score_gemma":0.001742505,"domain_scores_codex":[0.9993436,0.0003801439,0.00005056222,0.00008882802,0.00008180115,0.00005508371],"domain_scores_gemma":[0.9992187,0.0002296449,0.000288547,0.0000647947,0.00005781511,0.0001406036],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8344373,0.01125896,0.01451221,0.001732448,0.004719192,0.0001865188,0.0001208985,0.001787266,0.02226943,0.0001103431,0.001657577,0.1072079],"study_design_scores_gemma":[0.7248825,0.2258497,0.03987913,0.00009667047,0.003029519,0.0003384302,0.00004534434,0.0008058735,0.002414028,0.0001329478,0.002500709,0.00002513209],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9852737,0.008833434,0.0006564335,0.0003164448,0.0000588959,0.002009969,0.001413308,0.00006881243,0.001369063],"genre_scores_gemma":[0.9939831,0.002536621,0.0004926965,0.0003165358,0.0001037519,0.0008791511,0.001253167,0.00001059462,0.0004243071],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00328954,"threshold_uncertainty_score":0.01200283,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009780463777112593,"score_gpt":0.2961600474988715,"score_spread":0.2863795837217589,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}